1. Introduction {#sec1}
===============

Cancer is a major public health problem and causes huge burdens on developed and developing countries. It is the third leading cause of death in China and ranks second in the USA \[[@B1], [@B2]\]. Although great progress has been achieved in the diagnosis and treatment of cancer, effective treatment for many cancer patients is still lacking. In view of the current situation, there has been great interest in prognostic biomarkers because of their usefulness in predicting clinical outcomes and guiding therapy \[[@B3]--[@B8]\].

Previous studies have investigated the correlations between serum lipid levels and human cancers \[[@B9], [@B10]\]. Serum cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were shown to be associated with the prognosis in multiple human cancers, such as colorectal cancer, liver cancer, and breast cancer \[[@B11]--[@B13]\]. As the major protein component of plasma HDL, apolipoprotein A-I (ApoA-I) synthesized in the liver and small intestine has been reported to be associated with clinical survival in multiple human cancers, including gastric cancer, nasopharyngeal carcinoma, and breast cancer \[[@B14]--[@B17]\]. However, the results on the clinical value of serum ApoA-I as a useful indicator have been debatable and inconsistent, and given the limited sample size and varied methodologies of individual studies, we therefore conducted this meta-analysis to provide a systematic evaluation of the significance of serum ApoA-I as a promising prognostic marker based on all related published data.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy and Study Selection {#sec2.1}
----------------------------------------

PubMed, Cochrane Library, Web of Science, Embase, Wanfang and China National Knowledge Infrastructure (CNKI) were comprehensively searched by the end of May 20, 2018. The search terms used were "apolipoprotein A-I," "ApoA-I," "apolipoprotein" combining with "tumor," "neoplasms," "malignancy," "carcinoma" OR "cancer." The search language was limited to English and Chinese. The references of the retrieved articles were also checked to obtain relevant studies.

Published studies that met the following criteria were included: (1) the study investigated the survival outcomes of human malignancies with low ApoA-I level versus high ApoA-I levels, (2) a cutoff value to identify pretreatment low/high ApoA-I level was given, (3) complete information for assessment of hazard ratios (HRs) and the corresponding 95% CIs for cancer prognosis were included, and (4) all patients were divided into two groups based on serum ApoA-I level.

A study was excluded if it was a nonoriginal study (review, comments, editorial, or abstract) or no useful data was available.

2.2. Data Extraction and Quality Assessment {#sec2.2}
-------------------------------------------

The data from all studies were independently extracted by two reviewers according to an extraction template. The general information included first author, country, year of publication, included time, total sample size, survival type, follow-up period, cutoff value, cutoff selection, treatment methods, and disease stage. The HRs along with 95% CI were directly obtained from published articles, and the multivariate analysis mode was preferred. In this meta-analysis, an HR \< 1 indicated a worse prognosis for subjects with low ApoA-I. If a study considered cases with low ApoA-I as a reference, then the data were converted to HR estimations that considered cases with high ApoA-I as a reference group to reflect the impact of low ApoA-I levels on cancer patients. The Newcastle--Ottawa scale (NOS) was utilized to assess the quality of the included studies, and a study with a NOS score ≥ 6 was considered to be of high quality.

2.3. Statistical Analysis {#sec2.3}
-------------------------

All pooled analyses were conducted using STATA 12.0 software (Stata, College Station, TX, USA). For the prognostic index, e.g., the overall survival (OS), HR and corresponding 95% CI were used as the summary measure. The chi-square test and *I*^2^ statistic were used to evaluate the heterogeneity. *I*^2^ \> 50% or *p* \< 0.1 determined significant heterogeneity, and then the random-effect model was applied. Visual funnel diagrams and Begg\'s test and Egger\'s test were utilized to assess the potential publication bias. Sensibility analysis was performed to evaluate the robustness of the combined results. All *p* values \< 0.05 were regarded as statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of the Studies {#sec3.1}
-----------------------------------

The detailed steps involved in the literature search are shown in [Figure 1](#fig1){ref-type="fig"}. After reading the full text and further examination according to the selection criteria, ultimately, 13 publications (including 14 studies) \[[@B14]--[@B26]\] containing 9295 patients were included in this systematic review and meta-analysis.

All were retrospective studies, and a total of 9295 cancer patients were included from 13 studies that were carried out in China and one study from Finland. The sample size varied from 144 to 1927. With respect to prognostic outcomes, 13 studies reported OS, 1 covered disease-specific survival (DSS), 1 covered cancer-specific survival (CSS), 3 covered disease-free survival (DFS), 1 reported progression-free survival (PFS), and 2 reported total time to recurrence (TTR), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). For calculating the prognostic values of serum ApoA-I, CSS was integrated into the meta-analysis of DSS, and PFS was integrated into the meta-analysis of DFS. Furthermore, as for cancer type, 10 different types of cancers were investigated, including non-small cell lung cancer (NSCLC); bladder cancer; gastric cancer (GC); nasopharyngeal carcinoma (NPC); breast cancer (BC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL); esophageal squamous cell carcinoma (ESCC); and renal cell carcinoma (RCC). The NOS evaluating the quality of included studies varied from 6 to 8. The main characteristics of the included studies are presented in [Table 1](#tab1){ref-type="table"}.

3.2. Apolipoprotein A-I Level and OS {#sec3.2}
------------------------------------

A total of 13 studies with 8099 subjects was involved in the meta-analysis of OS. Because of the significant heterogeneity among studies (*I*^2^ = 57.9%, *p* = 0.005), the random-effect model was applied. As shown in [Figure 2](#fig2){ref-type="fig"}, the results indicated that the low ApoA-I group was significantly associated with shortened OS time (HR = 0.52, 95% CI: 0.44--0.61, *p* \< 0.001).

3.3. Subgroup Analysis {#sec3.3}
----------------------

The subgroup analysis for OS was conducted to further explore the correlation between ApoA-I level and various cancers. The results showed that the ApoA-I level could serve as a prognostic biomarker especially in NPC (HR = 0.63, 95% CI: 0.54--0.73, *p* \< 0.001), CRC (HR = 0.48, 95% CI: 0.19--0.76, *p* \< 0.001), and HCC (HR = 0.46, 95% CI: 0.27--0.65, *p* \< 0.001). As shown in [Table 2](#tab2){ref-type="table"}, the subgroup analyses were implemented based on cancer type, cutoff value selection, stages, follow-up time, analysis models, and treatments. The calculated pooled HR values were significantly less than 1.0 in those subgroup analyses, which all suggested that low ApoA-I level was a significant unfavorable prognostic factor for OS.

3.4. Apolipoprotein A-I Level and Secondary Outcomes {#sec3.4}
----------------------------------------------------

We also investigated the relationships between and serum ApoA-I level and secondary outcomes in cancer patients. The detailed results are provided in [Table 3](#tab3){ref-type="table"}, and we found that lower Apo A-I was associated with poor CSS (HR: 0.47, 95% CI: 0.19--0.76, *p* \< 0.01) in cancers, and low ApoA-I level was a prognostic factor for inferior TTR (HR: 0.43, 95% CI: 0.29--0.58, *p* \< 0.01) in HCC, LRFS (HR: 0.58, 95% CI: 0.42--0.74, *p* \< 0.01) and DMFS (HR: 0.65, 95% CI: 0.41--0.89, *p* \< 0.01) in NPC, and DFS (HR: 0.64, 95% CI: 0.43--0.84, *p* \< 0.01) in various cancers.

3.5. Publication Bias {#sec3.5}
---------------------

Begg\'s plot is shown in [Figure 3](#fig3){ref-type="fig"}, and Begg\'s test and Egger\'s test showed that there was potential publication bias in OS (Pr~Begg\'s\ test~ \> \|*z*\| = 0.006 (continuity corrected); Pr~Egger\'s\ test~ \> \|*z*\| = 0.005). Then, the "trim and fill method" was also adopted, and after correction, the adjusted pooled HR was 0.555 (95% CI: 0.480--0.642, *p* \< 0.001), which indicated that no significant publication bias existed.

3.6. Sensitivity Analysis {#sec3.6}
-------------------------

The results indicated that any individual study had little effect on the overall results ([Figure 4](#fig4){ref-type="fig"}), which suggested that our results were relatively stable and credible.

4. Discussion {#sec4}
=============

ApoA-I belongs to the apolipoprotein A1/A4/E family, and it plays pivotal roles in both lipid metabolism (such as liver excretion of cholesterol, intracellular reuse of fatty acids, and as an important carrier and cofactor) and diverse human diseases \[[@B27]--[@B31]\]. It is well known that systemic inflammatory responses are actively involved in oncogenesis, progression, and survival prediction in cancer patients \[[@B32]--[@B34]\]. ApoA-I, as an indispensable component of HDL, inhibits monocyte chemotaxis and recruitment and was shown to be involved in inflammatory reactions, and ApoA-I/HDL can be activated and participate in antitumor activities in mature immune systems \[[@B31], [@B35]\]. ApoA-I can also inhibit tumor progression and protect against tumor development in vivo and in vitro. It was reported that ApoA-I established antitumor properties by interacting with C1QBP in colon cancer, and ApoA-I could also inhibit colitis-propelled carcinogenesis and modulate tumorigenicity and immunogenicity \[[@B36]--[@B39]\]. Studies also demonstrated the antitumorigenic effects of ApoA-I in vivo and that ApoA-I could potently suppress tumor growth and metastasis in vivo and improve survival in mouse tumor models \[[@B40], [@B41]\]. Additionally, ApoA-I exerted multiple functional effects in the tumor microenvironment \[[@B31], [@B41]\].

As far as we know, this is the first meta-analysis that has provided an updated understanding of the prognostic value of the serum ApoA-I level in various malignancies. After a synthesized literature search, a total of 13 published articles was collected involving a total of 9295 patients. From the pooled results, we found that a low level of serum ApoA-I was significantly associated with poor OS (HR = 0.52, 95% CI: 0.44--0.61) in human cancers. Furthermore, we also investigated the prognostic values of ApoA-I level in certain types of cancers and found that the pretreatment of ApoA-I level could act as a prognostic indicator in NPC (HR = 0.63, 95% CI: 0.54--0.73), CRC (HR = 0.48, 95% CI: 0.19--0.76), and HCC (HR = 0.46, 95% CI: 0.27--0.65). The subgroup analyses further revealed the prognostic significance of ApoA-I for OS in cancer patients. In addition, the relationships between serum ApoA-I level and secondary outcomes were also investigated, and the ApoA-I level was found to be associated with CSS (HR: 0.47, 95% CI: 0.19--0.76) in cancers, and the ApoA-I level might be a prognostic indicator for TTR (HR: 0.43, 95% CI: 0.29--0.58) in HCC, LRFS (HR: 0.58, 95% CI: 0.42--0.74) and DMFS (HR: 0.65, 95% CI: 0.41--0.89) in NPC, and DFS (HR: 0.64, 95% CI: 0.43--0.84) in cancers. Thus, the serum ApoA-I level might be a candidate biomarker with clinical utility in human malignant tumors.

Several limitations should be acknowledged in our meta-analysis. First, the total sample size was insufficient, and the number of studies included was also relatively small. Second, most of the participants were Chinese, and only one study was conducted with a European cohort. Third, only eligible articles published in English or Chinese were included in this meta-analysis. Fourth, potential bias might exist for OS in studies, although the "trim and fill method" was adopted and no significant bias was found. The sensitivity analysis also indicated the robustness of the pooled HR for OS. In addition, there was obvious heterogeneity for OS, and the heterogeneity could not be totally eliminated by subgroup analysis. Finally, the cutoff values for low ApoA-I level varied in different studies.

In summary, our meta-analysis showed that pretreatment low ApoA-I level was related to worse survival in patients with various tumors. Serum ApoA-I level might be a powerful and noninvasive biomarker to predict cancer prognosis. However, before ApoA-I levels are routinely applied in clinical management, large-scale and well-designed studies with unified cutoff values are necessary to validate our results.

Our deepest gratitude goes to the editor and anonymous reviewer for their expertise and careful work and thoughtful suggestions that have helped improve this paper substantially.
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###### 

Main characteristics of all included studies.

  Study      Year   Cancer type      Country   Included time   Total sample   Follow-up   Cutoff value   Cutoff selection   Treatment methods   Stage           Survival type         NOS
  ---------- ------ ---------------- --------- --------------- -------------- ----------- -------------- ------------------ ------------------- --------------- --------------------- -----
  Chen S     2018   NSCLC            China     2008--2010      141            ≥5 years    1.17 g/l       X-tile software    Mixed               Mixed           OS                    6
  Shang Z    2018   Bladder cancer   China     2004--2011      470            ≥5 years    1.19 g/l       ROC analysis       With surgery        No metastasis   OS, CSS               7
  Ma M       2018   GC               China     2005--2010      1201           ≥5 years    1.4 g/l        X-tile software    With surgery        Mixed           OS                    8
  Chang H    2018   NPC              China     2010--2011      1927           ≥5 years    1.125 g/l      ROC analysis       No surgery          No metastasis   OS, DFS, LRFS, DMFS   8
  Li X       2017   BC               China     2008--2011      1044           ≥5 years    1.56 g/l       ROC analysis       With surgery        No metastasis   OS, DFS               7
  Quan Q     2017   CRC              China     2005--2013      721            ≥5 years    1.105 g/l      ROC analysis       No surgery          Metastasis      OS                    7
  Sirnio P   2017   CRC              Finland   2006--2010      144            ≥5 years    1.235 g/l      ROC analysis       With surgery        Mixed           OS                    6
  Ma XL-1    2016   HCC              China     2012--2015      224            \<5 years   1.04 g/l       X-tile software    With surgery        Mixed           OS, TTR               7
  Ma XL-2    2016   HCC              China     2012-2013       219            \<5 years   1.04 g/l       X-tile software    With surgery        Mixed           OS, TTR               6
  Quan Q     2016   ENKTL            China     2002--2014      236            ≥5 years    0.95 g/l       ROC analysis       No surgery          Mixed           OS, PFS               7
  Wang XP    2016   ESCC             China     2007--2009      210            ≥5 years    1.21 g/l       ROC analysis       With surgery        Mixed           OS                    6
  Guo S      2016   RCC              China     2000--2012      755            ≥5 years    1.04 g/l       ROC analysis       With surgery        Mixed           OS, DFS               7
  Luo XL     2015   NPC              China     2004--2007      1196           ≥5 years    1.025 g/l      ROC analysis       No surgery          No metastasis   DSS, LRFS, DMFS       8
  Jiang R    2014   NPC              China     2003--2009      807            ≥5 years    1.065 g/l      ROC analysis       No surgery          Metastasis      OS                    7

NSCLC: non-small cell lung cancer; GC: gastric cancer; NPC: nasopharyngeal carcinoma; BC: breast cancer; CRC: colorectal cancer; HCC: hepatocellular carcinoma; ENKTL: extranodal natural killer (NK)/T-cell lymphoma, nasal type; ESCC: esophageal squamous cell carcinoma; RCC: renal cell cancer; OS: overall survival; CSS: cancer-specific survival; TTR: time to recurrence; DFS: disease-free survival; PFS: progression-free survival; DSS: disease-specific survival; DMFS: distant metastasis-free survival; LRFS: locoregional recurrence-free survival; ROC: the receiver operating characteristic curve.

###### 

Results of subgroup analysis of pooled HRs of OS.

  Stratified analysis            No. of studies   Pooled HR (95% CI)   *p* value   Heterogeneity   
  ------------------------------ ---------------- -------------------- ----------- --------------- -------
  \(1\) Cancer type                                                                                
   Gastrointestinal cancer       6                0.55 (0.43--0.68)    \<0.001     52.1            0.064
   Non-gastrointestinal cancer   7                0.50 (0.37--0.63)    \<0.001     63.9            0.011
  \(2\) Cutoff value selection                                                                     
   ROC analysis                  9                0.52 (0.41--0.63)    \<0.001     62.1            0.007
   X-tile software               4                0.52 (0.35--0.69)    \<0.001     59.4            0.061
  \(3\) Stage                                                                                      
  No metastasis                  3                0.56 (0.31--0.81)    \<0.001     64.7            0.059
  Metastasis                     2                0.63 (0.53--0.72)    \<0.001     0.0             0.773
  Mixed                          8                0.48 (0.36--0.60)    \<0.001     60.9            0.012
  \(4\) Follow-up time                                                                             
   \<5 years                     2                0.46 (0.27--0.65)    \<0.001     0.0             0.878
   ≥5 years                      11               0.53 (0.43--0.63)    \<0.001     64.1            0.002
  \(5\) Analysis modes                                                                             
   Univariate analysis           2                0.73 (0.57--0.88)    \<0.001     0.0             0.707
   Multivariate analysis         11               0.49 (0.41--0.58)    \<0.001     53.6            0.018
  \(6\) Treatments                                                                                 
   Mixed                         1                0.39 (0.24--0.63)    \<0.001     ---             ---
   No surgery                    4                0.55 (0.39--0.71)    \<0.001     73.1            0.011
   With surgery                  8                0.53 (0.40--0.65)    \<0.001     52.5            0.040

###### 

Analyses of secondary outcomes for ApoA-I in cancers.

  Secondary outcomes   No. of studies   No. of cases   Pooled HR (95% CI)   *p* value   Heterogeneity   
  -------------------- ---------------- -------------- -------------------- ----------- --------------- --------
  CSS                  2                1666           0.47 (0.19--0.76)    \<0.001     77.5            Random
  TTR                  2                443            0.43 (0.29--0.58)    \<0.001     0.0             Fixed
  LRFS                 2                3123           0.58 (0.42--0.74)    \<0.001     0.0             Fixed
  DMFS                 2                3123           0.65 (0.41--0.89)    \<0.001     73.0            Random
  DFS                  4                3962           0.64 (0.43--0.84)    \<0.001     65.9            Random
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